How can potential individual-level risk factors for adverse drug reactions, identified in anonymous spontaneous reports, be tested in a clinical setting?

Better understanding of genetic variation – between individuals and subpopulations – can inform more refined choices of drugs and doses. A new ISoP group is set to drive progress.

Our genes contribute anything from 15 to 95% of how we react to medicines. Why is this the case, and when is genetic testing necessary to avoid the risk of potential side effects?